Trial watch: dexmedetomidine in cancer therapy

ABSTRACTDexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery...

Full description

Bibliographic Details
Main Authors: Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2327143

Similar Items